Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Systematic transcriptomic analysis enables targeted drug repurposing for neurotropic flavivirus infections

ABSTRACT: Emerging mosquito-borne orthoflaviviruses like WNV and USUV pose global health risks due to rapid spread, severe neurological effects, and the lack of approved antivirals. This study used transcriptomic and bioinformatic analyses to uncover host–virus interactions and key molecular pathways. Based on these findings, approved drugs with potential antiviral activity were prioritized, and two were selected for experimental validation. The results highlight how integrating transcriptomic profiling with drug repurposing can accelerate the discovery of antiviral strategies against emerging viruses.

ORGANISM(S): Chlorocebus sabaeus

PROVIDER: GSE309915 | GEO | 2026/06/02

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Systematic transcriptomic analysis enables targeted drug repurposing for neurotropic flavivirus infections

Project description:Systematic transcriptomic analysis enables targeted drug repurposing for neurotropic flavivirus infections

| PRJNA1363992 | ENA

Mosquito- and tick-borne orthoflavivirus infections dysregulate microcephaly-associated genes in human neural progenitor cells

Project description:Human neural progenitor cell (hNPC) transcriptomic responses to infections with Zika virus (ZIKV), Powassan virus (POWV), or two strains of West Nile virus were analyzed at three times after infection in a single batch of hNPCs differentiated from induced pluripotent stem cells. The WNV infections displayed the fastest replication kinetics but the POWV infection produced the highest viral yield. All four infections upregulated common and unique innate immune and antiviral response genes by 12 hpi and induced upregulation of stress pathway genes by 24 hpi. The WNV infections downregulated cell cycle genes earlier than the ZIKV or POWV infections. Transcription factors regulating gene expression changes were predicted. All four orthoflaviviruses dysregulated the expression of 262 microcephaly-associated genes, with virus-specific differences in the extent of dysregulation. The data suggest that fetal hNPC infection in utero by each of the four orthoflaviviruses studied could induce neurodevelopmental disorders.

2026-04-02 | GSE309623 | GEO

Machine Learning Identifies Candidates for Drug Repurposing in Alzheimer's Disease

Project description:Clinical trials of novel therapeutics for Alzheimer's Disease (AD) have consumed a large amount of time and resources with largely negative results. Repurposing drugs already approved by the Food and Drug Administration (FDA) for another indication is a more rapid and less expensive option. In this study, we profile 80 FDA-approved and clinically tested drugs in neural cell cultures, with the goal of producing a ranked list of possible repurposing candidates.

2021-01-14 | GSE164788 | GEO

Identification of Antiviral Roles for the Exon-Junction Complex and Nonsense-Mediated Decay in Flaviviral Infection

Project description:West Nile virus (WNV) is an emerging mosquito-borne flavivirus, related to dengue virus and Zika virus. To gain insight into host pathways involved in WNV infection, we performed a systematic affinity-tag purification mass spectrometry (AP-MS) study to identify 259 WNV-interacting human proteins. RNAi screening revealed 26 genes that both interact with WNV proteins and influence WNV infection. We found that WNV, dengue and Zika virus capsids interact with a conserved subset of proteins that impact infection. These include the exon-junction complex (EJC) recycling factor, PYM1, which is antiviral against all three viruses. The EJC has roles in nonsense-mediated decay (NMD), and we found that both the EJC and NMD are antiviral. Mechanistically, we found that the EJC protein RBM8A directly binds WNV RNA. To counteract this antiviral defense, flavivirus infection inhibits NMD and the interaction of capsid with PYM1 interferes with EJC protein function and localization. Moreover, depletion of PYM1 attenuates RBM8A binding to viral RNA, suggesting that WNV sequesters PYM1 to protect viral RNA from decay. Together, these data suggest a complex interplay between the virus and host in regulating NMD and the EJC complex.

2019-11-14 | PXD011728 | Pride

A genus-wide interaction atlas across NS4B orthologues identifies a conserved role for UFMylation in orthoflavivirus replication (NS4B Effectome - Global Proteome)

Project description:Orthoflavivirus infections represent an increasing public health burden, with several members of the genus emerging or re-emerging globally. Despite the availability of few vaccines, no antiviral drugs are currently licensed for the treatment of orthoflavivirus infections. Several pre-clinical studies identified the non-structural protein 4B (NS4B), one of the least characterized viral proteins within the orthoflavivirus genus, as the most promising target for the development of potent direct-acting antivirals. However, its functional roles in viral replication are still elusive. Here, we employ an integrated proteomic approach to systematically identify cellular targets of NS4B across eight prototypic orthoflaviviruses and characterize their influence on the human proteome. Using this approach, we mapped high-confidence NS4B-interacting human proteins across the genus, underlying potentially divergent mechanisms of host adaptation across orthoflaviviruses spanning diverse pathologies and vector preferences. Among these, we unveil a novel function for UBA5, the E1-activating enzyme of the UFMylation pathway, in orthoflavivirus replication. Mechanistically, we map associations of distinct viral proteins with multiple members of the UFMylation pathway, which are selectively recruited to sites of viral replication to promote mitochondrial respiration. Finally, we demonstrate that pharmacological inhibition of UFMylation exerts potent antiviral activity in vitro and in vivo. This integrative study provides a rational framework for a system-level understanding of orthoflavivirus NS4B effector functions and sheds light on a conserved and unconventional role for UFMylation in orthoflavivirus replication.

2026-03-10 | PXD063404 | Pride

A genus-wide interaction atlas across NS4B orthologues identifies a conserved role for UFMylation in orthoflavivirus replication (NS4Bome)

2026-03-10 | PXD063343 | Pride

RIPK3-dependent transcriptional program in flavivirus-infected neurons

Project description:Here, we characterize RIPK3-dependent transcriptional responses in cortical neurons following infection with neurotropic flaviviruses. Neurons were infected with either Zika virus (ZIKV) strain MR766 at an MOI of 0.1, West Nile virus (WNV) strain TX 2002-HC at an MOI of 0.001, or a saline mock solution. Neurons were derived from mice lacking RIPK3 expression (Ripk3-/-) or wildtype controls. These studies revealed a number of antiviral genes whose upregulation following viral infection is absent in neurons lacking RIPK3, a subset of which were validated using qRT-PCR.

2018-11-06 | GSE122121 | GEO

Repurposing statins and phenothiazines to treat chemoresistant neuroblastoma

Project description:<p>Relapse and treatment resistance are common in children with high-risk neuroblastoma, and novel therapies are needed. Conventional drug discovery is slow, expensive, often fails in practice, and consequently falls short in addressing pediatric and rare conditions. In such instances, drug repurposing is a promising strategy. Here, we used two independent in silico prediction tools including machine learning to identify approved drugs for repurposing against neuroblastoma. The combination of statins and phenothiazines showed strong synergistic effects in human neuroblastoma organoids, decreased tumor growth and prolonged survival in MYCN-amplified neuroblastoma patient-derived xenografts. The drug combination altered cholesterol metabolism through two different mechanisms and induced a phenotypic change towards an adrenergic state in vitro, which was associated with enhanced chemosensitivity. Integration of the drug combination into standard-of-care chemotherapy regressed tumors and prolonged survival in chemoresistant patient-derived xenografts. Thus, a combination of safe and approved medications added to standard-of-care chemotherapy outperforms chemotherapy alone in chemoresistant neuroblastoma.</p>

2025-11-13 | MTBLS13246 | MetaboLights

Human liver-derived organoids recapitulate Oropouche virus infection and manifestation, enabling antiviral drug discovery

Project description:Oropouche virus (OROV) is a neglected, re-emerging arbovirus that typically causes self-limiting febrile illness but can also result in severe complications. Currently, there are no approved vaccines or treatments for OROV infection. We integrated clinical data from OROV-infected patients with human liver-derived organoid models to investigate the virus's impact on the liver and evaluate repurposed antivirals. Patient blood tests show elevated liver enzymes, suggesting OROV-associated hepatic dysfunction. OROV isolates productively infect liver organoids and induce severe cellular damage. Transcriptomic profiling reveals strong virus-host interactions, including activation of interferon-stimulated genes and cell death pathways. Pharmacological inhibition of the interferon pathway enhances OROV replication, whereas treatment with therapeutic interferon-α suppresses the infection. Molnupiravir, a clinically approved antiviral targeting viral RNA-dependent RNA polymerase, markedly inhibits OROV replication and mitigates virus-induced cytopathology. Combining molnupiravir with interferon-α resulted in synergistic antiviral activity, indicating the complementarity of virus-targeted and host-directed strategies.

2026-01-21 | GSE316780 | GEO

Repurposing FDA-approved drugs for the treatment of malignant peripheral nerve sheath tumors

Project description:Repurposing FDA-approved drugs for the treatment of malignant peripheral nerve sheath tumors

| PRJNA670744 | ENA